Bolt Biotherapeutics (BOLT) director reports option cancellations and new $5.44 grants

Rhea-AI Filing Summary

Bolt Biotherapeutics, Inc. director reported multiple stock option changes dated December 12, 2025. The reporting person agreed to cancellation of existing director stock options that had higher exercise prices such as $180.2, $60.6, $39.8, $32.6, $15.364 and $6.4 in exchange for new options having a lower exercise price of $5.44 per share. These new options cover blocks of common stock, including 1,393 and 1,810 shares. One new option for 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, and will vest in full upon a change in control of the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'CALLAGHAN BRIAN

(Last) (First) (Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$5.44	12/12/2025		A		1,393		(1)	11/16/2031	Common Stock	1,393	(2)	1,393	D
Director Stock Option (Right to Buy)	$180.2	12/12/2025		D			1,393	(1)	11/16/2031	Common Stock	1,393	(2)	0	D
Director Stock Option (Right to Buy)	$5.44	12/12/2025		A		1,810		(1)	03/23/2032	Common Stock	1,810	(3)	1,810	D
Director Stock Option (Right to Buy)	$60.6	12/12/2025		D			1,810	(1)	03/23/2032	Common Stock	1,810	(3)	0	D
Director Stock Option (Right to Buy)	$5.44	12/12/2025		A		1,250		(1)	06/09/2032	Common Stock	1,250	(4)	1,250	D
Director Stock Option (Right to Buy)	$39.8	12/12/2025		D			1,250	(1)	06/09/2032	Common Stock	1,250	(4)	0	D
Director Stock Option (Right to Buy)	$5.44	12/12/2025		A		1,250		(1)	06/11/2033	Common Stock	1,250	(5)	1,250	D
Director Stock Option (Right to Buy)	$32.6	12/12/2025		D			1,250	(1)	06/11/2033	Common Stock	1,250	(5)	0	D
Director Stock Option (Right to Buy)	$5.44	12/12/2025		A		1,100		(1)	06/11/2034	Common Stock	1,100	(6)	1,100	D
Director Stock Option (Right to Buy)	$15.364	12/12/2025		D			1,100	(1)	06/11/2034	Common Stock	1,100	(6)	0	D
Director Stock Option (Right to Buy)	$5.44	12/12/2025		A		1,100		(7)	05/26/2035	Common Stock	1,100	(8)	1,100	D
Director Stock Option (Right to Buy)	$6.4	12/12/2025		D			1,100	(7)	05/26/2035	Common Stock	1,100	(8)	0	D

Explanation of Responses:

1. The option is fully vested and exercisable.

2. The reporting person agreed to cancellation of an option granted on November 17, 2021, in exchange for a new option having a lower exercise price.

3. The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price.

4. The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price.

5. The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price.

6. The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price.

7. The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

8. The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.

	/s/ William P. Quinn, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bolt Biotherapeutics (BOLT) disclose in this Form 4?

The filing shows that a director of Bolt Biotherapeutics reported several director stock option transactions on December 12, 2025, cancelling previously granted options and receiving new options with a lower exercise price.

What is the relationship of the reporting person to Bolt Biotherapeutics (BOLT)?

The reporting person is identified as a Director of Bolt Biotherapeutics, Inc., and the Form 4 is indicated as being filed by one reporting person.

What are the key terms of the new stock options reported for BOLT?

The new director stock options have an exercise price of $5.44 per share and relate to Bolt Biotherapeutics common stock, with share amounts including 1,393, 1,810, 1,250 and 1,100 shares.

What happened to the previously granted options reported in the BOLT Form 4?

The reporting person agreed to cancellation of existing options that had higher exercise prices such as $180.2, $60.6, $39.8, $32.6, $15.364 and $6.4, in exchange for new options having a lower exercise price.

When do the reported Bolt Biotherapeutics director options expire?

The director stock options in the filing show expiration dates of November 16, 2031, March 23, 2032, June 9, 2032, June 11, 2033, June 11, 2034 and May 26, 2035, depending on the specific grant.

Are any of the new Bolt Biotherapeutics options subject to vesting conditions?

Yes. One option covering 1,100 shares will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, and will vest in full upon a change in control of the issuer, subject to continuous service.

Are any of the Bolt Biotherapeutics director options already fully vested?

According to the explanation, at least one of the reported director stock options is fully vested and exercisable as of the reported transactions.